$MDXG
MIMEDX GROUP, INC. Stock $mdxg

$mdxg Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000137633922000058 Filed on May 03, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$58.89M	$59.97M
YoY Change	-1.79%	-2.87%
Cost Of Revenue	$9.936M	$9.641M
YoY Change	3.06%	-3.83%
Gross Profit	$48.96M	$50.33M
YoY Change	-2.72%	-2.68%
Gross Profit Margin	83.13%	83.92%
Selling, General & Admin	$49.57M	$45.40M
YoY Change	9.18%	-3.28%
% of Gross Profit	101.25%	90.22%
Research & Development	$5.964M	$4.339M
YoY Change	37.45%	63.74%
% of Gross Profit	12.18%	8.62%
Depreciation & Amortization	$860.0K	$1.161M
YoY Change	-25.93%	-22.91%
% of Gross Profit	1.76%	2.31%
Operating Expenses	$55.53M	$49.74M
YoY Change	11.64%	0.3%
Operating Profit	-$9.300M	-$6.852M
YoY Change	35.73%	-50.15%
Interest Expense	-$1.126M	-$1.470M
YoY Change	-23.4%	-38.49%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00
YoY Change		-100.0%
Pretax Income	-$10.43M	-$8.324M
YoY Change	25.25%	-48.38%
Income Tax	$63.00K	$58.00K
% Of Pretax Income
Net Earnings	-$10.49M	-$8.382M
YoY Change	25.14%	73.86%
Net Earnings / Revenue	-17.81%	-13.98%
Basic Earnings Per Share	-$0.11	-$0.09
Diluted Earnings Per Share	-$0.11	-$0.09
COMMON SHARES
Basic Shares Outstanding	111.6M shares	109.4M shares
Diluted Shares Outstanding	111.6M shares	109.4M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$75.68M	$84.70M
YoY Change	-10.65%	58.32%
Cash & Equivalents	$75.68M	$84.75M
Short-Term Investments
Other Short-Term Assets	$2.571M	$3.530M
YoY Change	-27.17%	-32.32%
Inventory	$13.17M	$11.58M
Prepaid Expenses	$6.136M
Receivables	$37.67M	$35.42M
Other Receivables	$680.0K	$10.00M
Total Short-Term Assets	$135.9M	$150.0M
YoY Change	-9.37%	29.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.12M	$11.04M
YoY Change	18.82%	-6.67%
Goodwill	$19.98M	$19.98M
YoY Change	0.0%	0.0%
Intangibles	$5.265M	$5.918M
YoY Change	-11.03%	-21.94%
Long-Term Investments
YoY Change
Other Assets	$172.0K	$344.0K
YoY Change	-50.0%	-31.2%
Total Long-Term Assets	$38.54M	$40.85M
YoY Change	-5.66%	-5.02%
TOTAL ASSETS
Total Short-Term Assets	$135.9M	$150.0M
Total Long-Term Assets	$38.54M	$40.85M
Total Assets	$174.4M	$190.8M
YoY Change	-8.58%	20.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.120M	$6.925M
YoY Change	17.26%	-29.34%
Accrued Expenses	$9.812M	$30.68M
YoY Change	-68.01%	0.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$36.59M	$55.41M
YoY Change	-33.96%	-13.01%
LONG-TERM LIABILITIES
Long-Term Debt	$48.24M	$47.80M
YoY Change	0.92%	-22.45%
Other Long-Term Liabilities	$4.553M	$3.624M
YoY Change	25.63%	12.06%
Total Long-Term Liabilities	$52.79M	$51.42M
YoY Change	2.66%	-20.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.59M	$55.41M
Total Long-Term Liabilities	$52.79M	$51.42M
Total Liabilities	$89.38M	$106.8M
YoY Change	-16.33%	-16.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$172.2M	-$159.8M
YoY Change	7.75%	49.41%
Common Stock	$114.0K	$113.0K
YoY Change	0.88%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$840.0K	$5.091M
YoY Change	-83.5%	-59.52%
Treasury Stock Shares	172.8K shares	1.083M shares
Shareholders Equity	-$7.434M	-$8.051M
YoY Change
Total Liabilities & Shareholders Equity	$174.4M	$190.8M
YoY Change	-8.58%	20.08%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$10.49M	-$8.382M
YoY Change	25.14%	73.86%
Depreciation, Depletion And Amortization	$860.0K	$1.161M
YoY Change	-25.93%	-22.91%
Cash From Operating Activities	-$10.22M	-$6.679M
YoY Change	53.06%	-45.62%
INVESTING ACTIVITIES
Capital Expenditures	$118.0K	$1.941M
YoY Change	-93.92%	-278.07%
Acquisitions
YoY Change
Other Investing Activities	$24.00K	$20.00K
YoY Change	20.0%
Cash From Investing Activities	-$148.0K	-$2.079M
YoY Change	-92.88%	91.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.036M	-$2.308M
YoY Change	-55.11%	6.02%
NET CHANGE
Cash From Operating Activities	-$10.22M	-$6.679M
Cash From Investing Activities	-$148.0K	-$2.079M
Cash From Financing Activities	-$1.036M	-$2.308M
Net Change In Cash	-$11.41M	-$11.07M
YoY Change	3.08%	-28.81%
FREE CASH FLOW
Cash From Operating Activities	-$10.22M	-$6.679M
Capital Expenditures	$118.0K	$1.941M
Free Cash Flow	-$10.34M	-$8.620M
YoY Change	19.97%	-22.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001376339
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-35887
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	MIMEDX GROUP, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2792552
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1775 West Oak Commons Ct NE
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Marietta
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30062
CY2022Q1	dei	City Area Code CityAreaCode	770
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	651-9100
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	MDXG
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	113352746	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75676000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87083000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37674000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40353000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	13170000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	11389000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6136000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6146000	USD
CY2022Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	680000	USD
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	743000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2571000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2809000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	135907000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	148523000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8759000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	9165000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4364000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4696000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	19976000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	19976000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5265000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5383000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	172000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	186000	USD
CY2022Q1	us-gaap	Assets Assets	174443000	USD
CY2021Q4	us-gaap	Assets Assets	187929000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8120000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7385000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17102000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23595000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9812000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9812000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1557000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1565000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	36591000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	42357000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48239000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48127000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4553000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4869000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	89383000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	95353000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	100000	shares
CY2022Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	100000	shares
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	100000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000	shares
CY2022Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	100000	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	92494000	USD
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	92494000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	187500000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	187500000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	82000	USD
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	113525178	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	113352410	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112703926	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111925216	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	114000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	113000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	165490000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	165695000	USD
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	172768	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	778710	shares
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	840000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	4017000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-172198000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-161709000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-7434000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	174443000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	187929000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	58894000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59967000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9936000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9641000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	48958000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	50326000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	49570000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45404000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5964000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4339000	USD
CY2022Q1	mdxg	Investigation Restatementand Related InvestigationRestatementandRelated	2552000	USD
CY2021Q1	mdxg	Investigation Restatementand Related InvestigationRestatementandRelated	7196000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	239000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9300000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6852000	USD
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1126000	USD
CY2021Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1472000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10426000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8324000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	58000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10489000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8382000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12075000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9850000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111615839	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109401383	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111615839	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109401383	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	82000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3998000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	166000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1191000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10489000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-7434000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-150000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	462000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3244000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	915000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3216000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8382000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-8051000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10489000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8382000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3998000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3244000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	860000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	1161000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	239000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	112000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	415000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	295000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	237000	USD
CY2022Q1	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	22000	USD
CY2021Q1	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	17000	USD
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	15000	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-236000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2679000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1781000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1221000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-11000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-910000	USD
CY2022Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-63000	USD
CY2021Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-54000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	298000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-319000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	456000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-936000	USD
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-6494000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2314000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	550000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-484000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-364000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-177000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10223000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6679000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	118000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1941000	USD
CY2022Q1	mdxg	Paymentsfor Application Costs Patent PaymentsforApplicationCostsPatent	54000	USD
CY2021Q1	mdxg	Paymentsfor Application Costs Patent PaymentsforApplicationCostsPatent	153000	USD
CY2022Q1	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	0	USD
CY2021Q1	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	15000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	24000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-148000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2079000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1191000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3216000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	166000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	915000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	7000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1036000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2308000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11407000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11066000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87083000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95812000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75676000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84746000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported unaudited condensed consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates regarding asset retirement obligations, estimates for contingent liabilities, the measurement of right of use assets and lease liabilities, management’s assessment of the Company’s ability to continue as a going concern, estimates of fair value of share-based payments, estimates of sales returns and allowances, and valuation of deferred tax assets.</span></div>
CY2022Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	39061000	USD
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	41540000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1387000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1187000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37674000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40353000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	223000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-21000	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	536000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	364000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7229000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6112000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5405000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4913000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	13170000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	11389000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	189000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	189000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	42201000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	42043000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	33442000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	32878000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8759000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	9165000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	860000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	1161000	USD
CY2022Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	11846000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5265000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	11791000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5383000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	239000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	513000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	684000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	684000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	289000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	134000	USD
CY2022Q1	mdxg	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	772000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3076000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	3209000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	2806000	USD
CY2022Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2444000	USD
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2630000	USD
CY2022Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	587000	USD
CY2021Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	788000	USD
CY2022Q1	mdxg	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	713000	USD
CY2021Q4	mdxg	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	694000	USD
CY2022Q1	mdxg	Accrued Administrative Fees Current AccruedAdministrativeFeesCurrent	565000	USD
CY2021Q4	mdxg	Accrued Administrative Fees Current AccruedAdministrativeFeesCurrent	559000	USD
CY2022Q1	mdxg	Accrued Rebates AccruedRebates	1147000	USD
CY2021Q4	mdxg	Accrued Rebates AccruedRebates	1343000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1147000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	992000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9812000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9812000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	50000000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2022Q1	mdxg	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	0	USD
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	50000000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10489000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8382000	USD
CY2022Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1586000	USD
CY2021Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1006000	USD
CY2022Q1	mdxg	Temporary Equity Accretionof Increasingrate Dividend Feature TemporaryEquityAccretionofIncreasingrateDividendFeature	0	USD
CY2021Q1	mdxg	Temporary Equity Accretionof Increasingrate Dividend Feature TemporaryEquityAccretionofIncreasingrateDividendFeature	462000	USD
CY2022Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1586000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1468000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12075000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9850000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111615839	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109401383	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12075000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9850000	USD
CY2022Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1586000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1468000	USD
CY2022Q1	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	-1586000	USD
CY2021Q1	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	-1468000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12075000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9850000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111615839	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109401383	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29459846	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30470089	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29459846	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30470089	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111615839	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109401383	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29459846	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30470089	shares
CY2020Q3	mdxg	Temporary Equity Conversion Price Per Share TemporaryEquityConversionPricePerShare	5.25
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	696582	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1315511	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.53
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y4M20D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1444845	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.18
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	124334	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.33
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.24
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1315511	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.53
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y4M20D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	696582	USD
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.006
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.007
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1034000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	1094000	USD
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	4000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	37000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	189000	USD
CY2022Q1	mdxg	Notes Receivable For Sale Of Property And Equipment NotesReceivableForSaleOfPropertyAndEquipment	0	USD
CY2021Q1	mdxg	Notes Receivable For Sale Of Property And Equipment NotesReceivableForSaleOfPropertyAndEquipment	75000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	287000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	159000	USD
CY2022Q1	mdxg	Fair Value Of Non Cash Consideration Received For Option Exercise FairValueOfNonCashConsiderationReceivedForOptionExercise	0	USD
CY2021Q1	mdxg	Fair Value Of Non Cash Consideration Received For Option Exercise FairValueOfNonCashConsiderationReceivedForOptionExercise	380000	USD
CY2022Q1	mdxg	Temporary Equity Deemed Dividends TemporaryEquityDeemedDividends	0	USD
CY2021Q1	mdxg	Temporary Equity Deemed Dividends TemporaryEquityDeemedDividends	462000	USD
CY2022Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	300000	USD
CY2022Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	400000	USD
CY2019Q1	mdxg	Contingency Loss Number Of Securities Class Actions ContingencyLossNumberOfSecuritiesClassActions	2	classAction
CY2022Q1	mdxg	Revenue From Contract With Customer Number Of Distribution Channels RevenueFromContractWithCustomerNumberOfDistributionChannels	2	distributionChannel
CY2022Q1	mdxg	Number Of Products NumberOfProducts	2	product
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	58894000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59967000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	58894000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59967000	USD

Files In Submission

Name	View Source	Status
0001376339-22-000058-index-headers.html	Edgar Link	pending
0001376339-22-000058-index.html	Edgar Link	pending
0001376339-22-000058.txt	Edgar Link	pending
0001376339-22-000058-xbrl.zip	Edgar Link	pending
a20220331-10qexhibit311.htm	Edgar Link	pending
a20220331-10qexhibit312.htm	Edgar Link	pending
a20220331-10qexhibit321.htm	Edgar Link	pending
a20220331-10qexhibit322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mdxg-20220331.htm	Edgar Link	pending
mdxg-20220331.xsd	Edgar Link	pending
mdxg-20220331_cal.xml	Edgar Link	unprocessable
mdxg-20220331_def.xml	Edgar Link	unprocessable
mdxg-20220331_htm.xml	Edgar Link	completed
mdxg-20220331_lab.xml	Edgar Link	unprocessable
mdxg-20220331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDXG
MIMEDX GROUP, INC. Stock $mdxg

2022 Q1 Form 10-Q Financial Statement

#000137633922000058 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDXG MIMEDX GROUP, INC. Stock $mdxg

2022 Q1 Form 10-Q Financial Statement

#000137633922000058 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDXG
MIMEDX GROUP, INC. Stock $mdxg